Sodium rabeprazole, a proton pump inhibitor class anti ulcer disease drug, is the sodium salt form of rabeprazole, which was first developed successfully by Eisai company in Japan under the trade name of boric acid, proton pump inhibitors act to reduce gastric acid secretion and stabilize the lesion site, thus achieving the effect of curing gastric and duodenal ulcers and gastro oesophageal reflux disease. Clinically, it is mainly used to treat acid related diseases, such as gastric and duodenal ulcer, peptic ulcer, gastroesophageal reflux disease, Zhuo AI syndrome, and so on.